Compare Abeona Therapeutics Inc (ABEO) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Credo Technology Group Holding Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Credo Technology Group Holding Ltd trades at $259.06 (market cap $45.95B). The key difference: Credo Technology Group Holding Ltd is far larger — about 123.1× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | CRDO | |
|---|---|---|
Market Cap | $373.32M | $45.95B |
Sector | Health | Technology |
52-Week High | $7.23 | $302.52 |
52-Week Low | $4.17 | $87.81 |
Enterprise Value | $228.22M | $44.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CRDO trades at $265.55, up 9.77% in 24 hours, with strong bullish momentum from moving averages and recent earnings beats. The stock shows robust fundamentals with 35.37% net income margin and 34.41% ROE, though valuations are elevated at P/E 105.8 and P/S 37.44. Recent news highlights AI-driven growth in connectivity solutions, with revenue surging 157% YoY in Q4 2026.
Outlook remains positive given analyst consensus of $273.33 price target and 86.7% buy ratings, but high valuations and competitive pressures pose risks. Continued execution on AI networking demand could drive further upside, while any slowdown in growth may trigger multiple compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
